Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.

BACKGROUND TZT-1027 (Soblidotin), a microtubule-depolymerizing agent, has antivascular activity which disrupts newly formed tumor vasculature. In this study, it was investigated whether TZT-1027 has also antiangiogenic activity preventing neovascularization. MATERIALS AND METHODS Antiangiogenic activities were evaluated in vivo in a chick embryo chorioallantoic membrane (CAM) assay and in vitro in a tube formation assay on human umbilical vein endothelial cells (HUVEC). RT-PCR and skimmed milk zymography analyses were performed to clarify the involvement of angiogenesis-related proteolytic enzymes and transcription factors. RESULTS TZT-1027 at doses of 0.01 and 0.06 microg/egg showed potent antiangiogenic activities in the CAM assay (80% and 100% inhibition, respectively), with no lethal toxicity to the chick embryo. TZT-1027 at doses of 0.01-10 ng/mL prevented tube formation, while 1-100 ng/mL disrupted the preformed vascular tube. However, mRNA and protein expression were unchanged. CONCLUSION TZT-1027 showed antiangiogenic activity at lower doses than it exhibited its antivascular activity. We believe it would exert its antiangiogenic activity, even if kept in a tumor at reduced concentrations to keep its antivascular activity to a minimum.

[1]  T. Natsume,et al.  Antivascular effects of TZT‐1027 (Soblidotin) on murine Colon26 adenocarcinoma , 2006, Cancer science.

[2]  G. Attard,et al.  A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Minami,et al.  Antitumor activity of TZT-1027 (Soblidotin). , 2006, Anticancer research.

[4]  T. Natsume,et al.  Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. , 2006, Anticancer research.

[5]  S. Rodenhuis,et al.  Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Ganser,et al.  Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  F. Shepherd,et al.  Angiogenesis inhibitors under study for the treatment of lung cancer. , 2003, Lung cancer.

[8]  C. Kanthou,et al.  The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.

[9]  K. Shirato,et al.  Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. , 2001, Biochemical and biophysical research communications.

[10]  P. Boström,et al.  Expression of collagenase‐3 (matrix metalloproteinase‐13) in transitional‐cell carcinoma of the urinary bladder , 2000, International journal of cancer.

[11]  T. Natsume,et al.  Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent , 2000, Apoptosis.

[12]  T. Mikami,et al.  TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death , 2000, Japanese journal of cancer research : Gann.

[13]  T. Natsume,et al.  Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with Tubulin , 2000, Japanese journal of cancer research : Gann.

[14]  H. Tsuda,et al.  Antimetastatic and antitumor effects of 2,4-diamino-6-(pyridine-4-yl)-1,3,5-triazine (4PyDAT) on the high lung metastatic colon 26 tumor in mice. , 2000, Anti-cancer drug design.

[15]  D. Rifkin,et al.  Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. , 1998, The Journal of surgical research.

[16]  M. Hudson,et al.  Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. , 1997, Journal of the National Cancer Institute.

[17]  T. Mikami,et al.  Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative , 1997, Japanese journal of cancer research : Gann.

[18]  K. Kihara,et al.  Bacillus Calmette‐Guérin Enhances Production and Secretion of Type IV Collagenases in Peripheral Blood Mononuclear Cells , 1997, Japanese journal of cancer research : Gann.

[19]  M. Abe,et al.  Ets‐1 regulates angiogenesis by inducing the expression of urokinase‐type plasminogen activator and matrix metalloproteinase‐1 and the migration of vascular endothelial cells , 1996, Journal of cellular physiology.

[20]  T. Mikami,et al.  Synthesis and antitumor activity of novel dolastatin 10 analogs. , 1995, Chemical & pharmaceutical bulletin.

[21]  H. Okada,et al.  Antitumor Effect of Arterial Administration of a Medium-Chain Triglyceride Solution of an Angiogenesis Inhibitor, TNP-470, in Rabbits Bearing VX-2 Carcinoma , 1995, Pharmaceutical Research.

[22]  M. Shimamura,et al.  Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic). , 1989, The Journal of antibiotics.

[23]  K. Kihara,et al.  Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells. , 2001, Anticancer research.

[24]  M. Hudson,et al.  Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines. , 1999, Advances in experimental medicine and biology.

[25]  G. Kimura,et al.  Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells , 1998, Urological Research.

[26]  G. Wang,et al.  Induction of the , 1996 .

[27]  Y. Nishiyama,et al.  Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition. , 1986, Experimental pathology.